• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫颈癌筛查中的持续性癌:未参与是最主要原因。

Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause.

作者信息

Marquardt Katrin, Büttner Heinz H, Broschewitz Ulf, Barten Malte, Schneider Volker

机构信息

Pathology Laboratory, Schwerin, Germany.

出版信息

Acta Cytol. 2011;55(5):433-7. doi: 10.1159/000331811. Epub 2011 Oct 8.

DOI:10.1159/000331811
PMID:21986170
Abstract

OBJECTIVE

It was the aim of this study to determine the screening history of all invasive cervical carcinomas between 2004 and 2009 in one of the Federal States of Germany.

STUDY DESIGN

The pooled data sets of all in-state laboratories, corrected and supplemented by data of the State Cancer Registry, were used. The screening histories of all patients, their age and tumor types were collated and analyzed.

RESULTS

Of 617 patients with invasive carcinoma of the cervix, 373 (60%) had not had a cervical smear within the past 5 years. In 188 patients (31%), an incomplete screening history was found, whereas only 9% of women had participated regularly. In non-participants, late tumor stages (stage T1B and higher) were predominant and found in 86%. In contrast, in the group with regular screening histories more than half of all cases (54%) were microinvasive carcinomas (stage T1A) with excellent prognosis. Lack of follow-up or refusal of treatment by patients played a minor yet significant role.

CONCLUSIONS

Non-participation is still by far the most common reason for persistent cases of cervical carcinoma in the German screening program.

摘要

目的

本研究旨在确定德国某联邦州2004年至2009年间所有浸润性宫颈癌的筛查史。

研究设计

使用了该州所有实验室的汇总数据集,并由州癌症登记处的数据进行校正和补充。整理并分析了所有患者的筛查史、年龄和肿瘤类型。

结果

在617例浸润性宫颈癌患者中,373例(60%)在过去5年内未进行过宫颈涂片检查。188例患者(31%)的筛查史不完整,而只有9%的女性定期参与筛查。在未参与者中,晚期肿瘤阶段(T1B期及更高)占主导,占86%。相比之下,在筛查史规律的组中,超过一半的病例(54%)为微浸润癌(T1A期),预后良好。患者缺乏随访或拒绝治疗起到了较小但显著的作用。

结论

在德国的筛查项目中,不参与筛查仍然是宫颈癌持续存在病例的最常见原因。

相似文献

1
Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause.宫颈癌筛查中的持续性癌:未参与是最主要原因。
Acta Cytol. 2011;55(5):433-7. doi: 10.1159/000331811. Epub 2011 Oct 8.
2
[Cervical cancer in Mecklenburg-Western Pomerania. Tumor stage, histological tumor type, age and screening participation of 985 patients].[梅克伦堡-前波美拉尼亚州的宫颈癌。985例患者的肿瘤分期、组织学肿瘤类型、年龄及筛查参与情况]
Pathologe. 2016 Feb;37(1):78-83. doi: 10.1007/s00292-015-0120-1.
3
Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening.意大利艾米利亚-罗马涅地区宫颈癌筛查史:确定改善宫颈癌筛查的优先事项
Eur J Cancer Prev. 2015 Mar;24(2):128-34. doi: 10.1097/CEJ.0000000000000035.
4
Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.采用 mRNA 人乳头瘤病毒检测和肉眼观察对宫颈癌进行初级筛查和分流。
Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.
5
PAX1 methylation as a potential biomarker for cervical cancer screening.PAX1 甲基化作为宫颈癌筛查的潜在生物标志物。
Int J Gynecol Cancer. 2014 Jun;24(5):928-34. doi: 10.1097/IGC.0000000000000155.
6
Clinical Significance of Atypical Squamous Cells of Undetermined Significance among Patients Undergoing Cervical Conization.宫颈锥切术患者中意义不明确的非典型鳞状细胞的临床意义
Asian Pac J Cancer Prev. 2015;16(18):8145-7. doi: 10.7314/apjcp.2015.16.18.8145.
7
Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China.中国中山43567名女性的宫颈癌筛查及潜在风险因素分析
Asian Pac J Cancer Prev. 2014;15(2):671-6. doi: 10.7314/apjcp.2014.15.2.671.
8
Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study.筛查频率和组织学类型影响宫颈癌筛查效果:一项全国性队列研究。
Taiwan J Obstet Gynecol. 2017 Aug;56(4):442-448. doi: 10.1016/j.tjog.2017.01.010.
9
Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.在细胞学结果异常不明确的女性中使用人乳头瘤病毒检测进行风险分层:一项全州监测项目的结果
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):36-42. doi: 10.1158/1055-9965.EPI-15-0669. Epub 2015 Oct 30.
10
Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.检测高危型(HR)人乳头瘤病毒(HPV)16、18 和 45 型在癌前宫颈病变中的诊断准确性的测定:初步数据。
J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

引用本文的文献

1
Evaluation of the applicability of internal controls on self-collected samples for high-risk human papillomavirus is needed.需要评估内部控制措施在自我采集样本用于高危型人乳头瘤病毒检测中的适用性。
BMC Womens Health. 2023 Nov 27;23(1):635. doi: 10.1186/s12905-023-02691-8.
2
Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC) on the Diagnostic Algorithm for the New Cervical Cancer Screening - Initial Data.宫颈病理学与阴道镜检查工作组(AGCPC)关于新宫颈癌筛查诊断算法的注册研究——初始数据
Geburtshilfe Frauenheilkd. 2023 Oct 5;83(10):1250-1262. doi: 10.1055/a-2159-7510. eCollection 2023 Oct.
3
Intervention to Increase Cervical Cancer Screening Behavior among Medically Underserved Women: Effectiveness of 3R Communication Model.
提高医疗服务不足女性宫颈癌筛查行为的干预措施:3R 沟通模式的有效性
Healthcare (Basel). 2023 May 5;11(9):1323. doi: 10.3390/healthcare11091323.
4
Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study.宫颈癌筛查异常后阴道镜检查未到场:一项基于人群的前瞻性队列研究。
BMC Womens Health. 2022 Jul 9;22(1):285. doi: 10.1186/s12905-022-01851-6.
5
Feasibility of Utilizing Social Media to Promote HPV Self-Collected Sampling among Medically Underserved Women in a Rural Southern City in the United States (U.S.).在美国南部一个农村城市中,利用社交媒体在美国医疗服务不足的女性中推广人乳头瘤病毒(HPV)自我采集样本的可行性。
Int J Environ Res Public Health. 2021 Oct 14;18(20):10820. doi: 10.3390/ijerph182010820.
6
CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection.CoCoss-Trial:用于 HPV 检测的自我采样设备的同期比较。
Int J Environ Res Public Health. 2021 Oct 2;18(19):10388. doi: 10.3390/ijerph181910388.
7
A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.美国机会性筛查中发生的宫颈癌的全州人群为基础的评估。
Gynecol Oncol. 2020 Nov;159(2):344-353. doi: 10.1016/j.ygyno.2020.08.033. Epub 2020 Sep 22.
8
Long-term protection of HPV test in women at risk of cervical cancer.HPV 检测对宫颈癌高危女性的长期保护作用。
PLoS One. 2020 Aug 27;15(8):e0237988. doi: 10.1371/journal.pone.0237988. eCollection 2020.
9
Systematic Comparison of Different Meta-analyses, Systematic Reviews and HTA Reports on Cervical Cancer Screening based on Cytology or HPV Test.基于细胞学或HPV检测的宫颈癌筛查不同Meta分析、系统评价和卫生技术评估报告的系统比较
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1081-1085. doi: 10.1055/s-0042-112457.
10
Method comparison between Munich II and III nomenclature for Pap smear samples.巴氏涂片样本的慕尼黑II级和III级命名法之间的方法比较。
J Turk Ger Gynecol Assoc. 2015 Nov 2;16(4):203-7. doi: 10.5152/jtgga.2015.0147. eCollection 2015.